Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;17(2):199-207.
doi: 10.1159/000516376. Epub 2021 Jul 19.

Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer

Kerstin Rhiem  1 , Bernd Auber  2 , Susanne Briest  3 , Nicola Dikow  4 , Nina Ditsch  5 , Neda Dragicevic  6 , Sabine Grill  7 , Eric Hahnen  1 , Judit Horvath  8 , Bernadette Jaeger  9 , Karin Kast  1 , Marion Kiechle  7 , Elena Leinert  10 , Susanne Morlot  2 , Michael Püsken  11 , Dieter Schäfer  12 , Sarah Schott  13 , Christopher Schroeder  14 , Ulrike Siebers-Renelt  8 , Christine Solbach  15 , Nana Weber-Lassalle  1 , Isabell Witzel  16 , Christine Zeder-Göß  5 , Rita K Schmutzler  1
Affiliations
Review

Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer

Kerstin Rhiem et al. Breast Care (Basel). 2022 Apr.

Abstract

Background: The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) has established a multigene panel (TruRisk®) for the analysis of risk genes for familial breast and ovarian cancer.

Summary: An interdisciplinary team of experts from the GC-HBOC has evaluated the available data on risk modification in the presence of pathogenic mutations in these genes based on a structured literature search and through a formal consensus process.

Key messages: The goal of this work is to better assess individual disease risk and, on this basis, to derive clinical recommendations for patient counseling and care at the centers of the GC-HBOC from the initial consultation prior to genetic testing to the use of individual risk-adapted preventive/therapeutic measures.

Keywords: BRCA1; BRCA2; Consensus; Hereditary breast cancer; Hereditary ovarian cancer; Panel testing.

PubMed Disclaimer

Conflict of interest statement

Christopher Schroeder reports research support from Illumina and Bristol Myers Squibb and institutional research support from Novartis.

References

    1. Waha A, et al. Konsensusempfehlung des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs zum Umgang mit Ergebnissen der Multigenanalyse. Geburtsh Frauenheilk. 2017;77:733–9.
    1. Weber-Lassalle N, Hauke J, Ramser J, et al. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast Cancer Res. 2018 Jan 24;20((1)):7. - PMC - PubMed
    1. Weber-Lassalle N, Borde J, Weber-Lassalle K, et al. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. Breast Cancer Res. 2019 Apr 29;21((1)):55. - PMC - PubMed
    1. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317((23)):2402–16. - PubMed
    1. Engel C, Fischer C, Zachariae S, et al. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance. Int J Cancer. 2020;146((4)):999–1009. - PubMed